Our data proved that HMGB3 activates MAPK/ERK signaling in ovarian cancer, as indicated by increased MEK1/2 and ERK1/2 phosphorylation, and the upregulation of its downstream molecules, including ETS-1, CCND1, and c-Myc. Here, MAP2K1 is linked to ovarian cancer.